Skip to main content

Table 1 Demographics

From: Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: a randomized clinical trial

Characteristics

Sugammadex 2 mg/kg ABW N = 38

Sugammadex 2 mg/kg IBW N = 38

Sugammadex 4 mg/kg ABW N = 38

Sugammadex 4 mg/kg IBW N = 36

Neostigmine+ Glycopyrrolate N = 38

 

Age (years)

48 ± 14

48 ± 15

47 ± 11

49 ± 12

48 ± 14

 

 Female sex

32 (84)

27 (71)

22 (58)

29 (81)

26 (68)

 

 White race

36 (95)

34 (90)

36 (95)

33 (92)

34 (90)

 

NMBA

 

 Rocuronium

27 (71)

25 (66)

26 (68)

27 (75)

28 (74)

 Vecuronium

11 (29)

13 (34)

12 (32)

9 (25)

10 (26)

BMI (kg/m2)

45.8 ± 4.5

47.2 ± 5.7

45.4 ± 5.0

46.5 ± 5.7

47.3 ± 4.7

 

ABW (kg)

127 ± 21

135 ± 17

131 ± 20

131 ± 21

135 ± 20

 

IBW (kg)

63 ± 7

65 ± 7

66 ± 7

63 ± 6

65 ± 8

 
  1. Subject’s ideal body weight is based on the gender category recorded at the time of randomization
  2. Data entries are either n (%) or mean ± SD
  3. BMI body mass index, ABW actual body weight, IBW ideal body weight, NMBA neuromuscular blocking agent, SD standard deviation